Study guide
18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
Key Takeaways Explain This Topic AI
Prescription drug misuse is the first example named in the blueprint's other use disorders category, covering opioid analgesics, stimulants, sedatives and over-the-counter agents.
Kratom contains mitragynine and 7-hydroxymitragynine, partial mu-opioid agonists that produce a genuine opioid withdrawal syndrome and respond to buprenorphine.
7-hydroxymitragynine concentrates sold as semi-synthetic products are far more potent than leaf kratom and have driven a rise in dependence presentations.
High-dose loperamide causes torsades de pointes and other ventricular dysrhythmias through cardiac sodium and potassium channel blockade, and is used both to self-treat opioid withdrawal and to achieve euphoria.
Dextromethorphan misuse causes NMDA-antagonist dissociation and serotonin toxicity, and combination products add acetaminophen hepatotoxicity risk.
Last updated: September 2026
18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
Quick Answer: The blueprint's category E names prescription drugs first . Beyond diverted opioids, stimulants and sedatives, the APRN must know kratom (mitragynine and 7-hydroxymitragynine — partial mu agonists producing true opioid withdrawal, responsive to buprenorphine), high-dose loperamide (sodium and potassium channel blockade causing torsades de pointes ), dextromethorphan (NMDA antagonism plus serotonin toxicity, with acetaminophen hepatotoxicity in combination products), gabapentinoids (potentiate opioid respiratory depression), and anabolic-androgenic steroids (hypogonadism and mood instability). None of these appear on a routine urine drug screen.
1. Diverted Prescription Medications
Class Diversion pattern APRN response
Opioid analgesics Leftover supplies from family or friends remain the most common source for first non-medical use Prescribe the smallest effective quantity; teach safe storage and disposal; review the PDMP
Prescription stimulants Misuse concentrated among students and young adults for performance; diversion from legitimately prescribed peers Confirm diagnosis before prescribing; use long-acting formulations; count-and-verify; PDMP at every refill
Benzodiazepines and Z-drugs Frequently obtained from multiple prescribers or illicit markets; counterfeit "alprazolam" pills commonly contain fentanyl or a novel benzodiazepine Avoid co-prescribing with opioids; taper rather than abruptly stop; counsel on counterfeit pill risk
Quetiapine Misused for sedation, including in correctional settings Recognize non-therapeutic requests; substitute evidence-based options for insomnia
Counterfeit-pill counseling is now essential. A pill that looks like a 30 mg oxycodone or a 2 mg alprazolam and did not come from a pharmacy should be assumed to contain illicitly manufactured fentanyl . This single teaching point is among the highest-yield overdose-prevention messages available.
2. Kratom (Mitragyna speciosa)
Element Detail
Active alkaloids Mitragynine (partial mu agonist, stimulant-like at low doses) and 7-hydroxymitragynine (far more potent mu agonist)
Dose-dependent effect Low dose: stimulant-like alertness and sociability. High dose: opioid-like analgesia and sedation
Why people use it Self-treatment of opioid withdrawal, chronic pain, fatigue and depression; legal and available in gas stations and smoke shops in most states
Dependence Genuine physical dependence with a true opioid withdrawal syndrome : myalgias, rhinorrhea, diarrhea, restlessness, insomnia, irritability
Treatment Buprenorphine treats kratom withdrawal and kratom use disorder effectively — a high-yield and frequently missed point
Toxicity Seizures, hepatotoxicity (cholestatic pattern), and deaths, usually with co-ingestants
Semi-synthetic concentrates Products marketed on 7-hydroxymitragynine content are far more potent than leaf kratom and have driven a surge in severe dependence; they are the subject of active federal scheduling attention
- Detection Not detected on standard opioid immunoassays; requires specific testing
- 3. Loperamide
An antidiarrheal and a peripherally acting mu-opioid agonist with minimal central penetration at therapeutic doses, because P-glycoprotein pumps it out of the CNS.
At supratherapeutic doses — often 50 to 200 tablets daily — the efflux system is saturated and central opioid effects occur. Users also co-ingest P-glycoprotein and CYP3A4 inhibitors (cimetidine, quinidine, grapefruit juice) to increase brain penetration.
Cardiotoxicity is the killer: loperamide blocks cardiac sodium channels (QRS widening, Brugada-like pattern) and potassium channels (QT prolongation) , producing torsades de pointes , ventricular tachycardia and cardiac arrest.
Management: cardiac monitoring, magnesium, sodium bicarbonate for QRS widening, overdrive pacing or isoproterenol for recurrent torsades. Naloxone reverses the opioid effect but not the cardiac channel blockade.
Clinical clue: a patient with opioid use disorder, a wide QRS and a prolonged QT with no other explanation. Ask directly about over-the-counter antidiarrheals.
4. Dextromethorphan
At high doses, DXM and its metabolite dextrorphan are NMDA antagonists , producing dose-dependent "plateaus" from mild euphoria to full dissociation resembling PCP.
Serotonin toxicity risk is real, especially combined with SSRIs, MAOIs, linezolid or tramadol.
CYP2D6 poor metabolizers achieve much higher dextromethorphan concentrations, and CYP2D6 inhibitors such as fluoxetine, paroxetine and bupropion have the same effect.
Combination products are the main hazard: cough and cold preparations containing acetaminophen (hepatotoxicity), chlorpheniramine (anticholinergic toxicity) or pseudoephedrine (sympathomimetic toxicity). Always check the full ingredient list.
Peak use is among adolescents , for whom access is trivial — another reason to ask explicitly about over-the-counter products.
5. Gabapentinoids
- Point Detail
- Mechanism Bind the alpha-2-delta subunit of voltage-gated calcium channels
Misuse Produces euphoria and potentiates opioid effect; widely misused in populations with opioid use disorder and in correctional settings
Mortality signal Concurrent gabapentinoid use increases opioid-related respiratory depression and overdose death risk
Scheduling Pregabalin is federally Schedule V ; gabapentin is not federally scheduled but is a controlled substance in a growing number of states
Withdrawal Abrupt discontinuation after chronic high-dose use can cause agitation, diaphoresis, confusion and seizures — taper rather than stop
6. Anabolic-Androgenic Steroids and Other Agents
Agent Key clinical points
Anabolic-androgenic steroids Schedule III; cause hypogonadotropic hypogonadism with testicular atrophy, infertility, gynecomastia, erythrocytosis, dyslipidemia, cardiomyopathy, hepatic injury with 17-alpha-alkylated oral agents, acne, and mood instability including aggression and depression during withdrawal; withdrawal depression carries suicide risk
Tianeptine ("gas station heroin") Mu-opioid agonist sold as a supplement; produces opioid dependence and withdrawal; multiple state bans
Phenibut GABA-B agonist sold online; severe dependence with a benzodiazepine-like withdrawal including delirium and seizures; requires a baclofen or benzodiazepine taper
Promethazine with codeine ("lean") Combination opioid and antihistamine; respiratory depression; frequently combined with alcohol
The unifying clinical lesson: ask about supplements, gas-station products and over-the-counter medicines by name . A patient answering "no" to "do you use drugs?" may be taking 60 loperamide tablets a day or a 7-hydroxymitragynine concentrate, and the routine urine drug screen will be entirely negative.